BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19031940)

  • 1. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
    Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
    Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
    Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
    Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.
    Nakazumi H; Sasano H; Iino K; Ohashi Y; Orikasa S
    Mod Pathol; 1998 Dec; 11(12):1165-70. PubMed ID: 9872646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
    Vargas PA; Cheng Y; Barrett AW; Craig GT; Speight PM
    J Oral Pathol Med; 2008 May; 37(5):309-18. PubMed ID: 18248354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
    Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
    Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
    Schmitt A; Saremaslani P; Schmid S; Rousson V; Montani M; Schmid DM; Heitz PU; Komminoth P; Perren A
    Histopathology; 2006 Sep; 49(3):298-307. PubMed ID: 16918977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer.
    Werynska B; Pula B; Muszczynska-Bernhard B; Piotrowska A; Jethon A; Podhorska-Okolow M; Dziegiel P; Jankowska R
    Anticancer Res; 2011 Sep; 31(9):2833-9. PubMed ID: 21868526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nestin as a marker in the classification of adrenocortical tumors.
    Lachenmayer A; Lichtenauer UD; Cox T; Schott M; Malendowicz LK; Goretzki PE; Cupisti K; Scherbaum WA; Bornstein SR; Willenberg HS
    Horm Metab Res; 2009 May; 41(5):397-401. PubMed ID: 19294612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
    Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
    Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of metallothionein expression with clinical progression of cancer in the oral cavity.
    Szelachowska J; Dziegiel P; Jelen-Krzeszewska J; Jelen M; Tarkowski R; Spytkowska B; Matkowski R; Kornafel J
    Anticancer Res; 2009 Feb; 29(2):589-95. PubMed ID: 19331208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis.
    Stojadinovic A; Brennan MF; Hoos A; Omeroglu A; Leung DH; Dudas ME; Nissan A; Cordon-Cardo C; Ghossein RA
    Mod Pathol; 2003 Aug; 16(8):742-51. PubMed ID: 12920217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer.
    Pastuszewski W; Dziegiel P; Krecicki T; Podhorska-Okolow M; Ciesielska U; Gorzynska E; Zabel M
    Anticancer Res; 2007; 27(1A):335-42. PubMed ID: 17352251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma.
    Wojnar A; Pula B; Piotrowska A; Jethon A; Kujawa K; Kobierzycki C; Rys J; Podhorska-Okolow M; Dziegiel P
    Anticancer Res; 2011 Sep; 31(9):3027-33. PubMed ID: 21868554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minichromosome Maintenance Proteins MCM-3, MCM-5, MCM-7, and Ki-67 as Proliferative Markers in Adrenocortical Tumors.
    Aporowicz M; Czopnik P; Kubicka E; Piotrowska A; Dziegiel P; Bolanowski M; Domoslawski P
    Anticancer Res; 2019 Mar; 39(3):1151-1159. PubMed ID: 30842144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indicators of malignancy of canine adrenocortical tumors: histopathology and proliferation index.
    Labelle P; Kyles AE; Farver TB; De Cock HE
    Vet Pathol; 2004 Sep; 41(5):490-7. PubMed ID: 15347821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p53 in adrenocortical tumours: clinicopathological correlations.
    McNicol AM; Nolan CE; Struthers AJ; Farquharson MA; Hermans J; Haak HR
    J Pathol; 1997 Feb; 181(2):146-52. PubMed ID: 9120717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma.
    Kato H; Miyazaki T; Fukai Y; Nakajima M; Sohda M; Takita J; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Asao T; Kuwano H
    J Surg Oncol; 2003 Sep; 84(1):24-30. PubMed ID: 12949987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma.
    Szelachowska J; Dziegiel P; Jelen-Krzeszewska J; Jelen M; Matkowski R; Pomiecko A; Spytkowska B; Jagas M; Gisterek I; Kornafel J
    Anticancer Res; 2006; 26(3B):2473-8. PubMed ID: 16821635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior.
    Papotti M; Volante M; Duregon E; Delsedime L; Terzolo M; Berruti A; Rosai J
    Am J Surg Pathol; 2010 Jul; 34(7):973-83. PubMed ID: 20534995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.